ESGIC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ESGIC (ESGIC).
Esgic contains butalbital (a barbiturate that enhances GABA-A receptor activity, producing sedation), acetaminophen (inhibits cyclooxygenase, particularly COX-2, in the CNS, reducing pain and fever), and caffeine (antagonizes adenosine receptors, providing vasoconstriction and adjuvant analgesic effect).
| Metabolism | Butalbital: hepatic via cytochrome P450 (CYP2C9, CYP2C19); Acetaminophen: hepatic via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation; also metabolized by CYP2E1 to toxic NAPQI; Caffeine: hepatic via CYP1A2. |
| Excretion | Renal: butalbital 60-70% unchanged, acetaminophen ~4% unchanged, caffeine ~1% unchanged. Biliary/fecal: minimal. |
| Half-life | Butalbital: ~35 hours; acetaminophen: ~2-3 hours; caffeine: ~3-6 hours. Clinical context: butalbital's long half-life leads to accumulation with repeated dosing, requiring cautious use. |
| Protein binding | Butalbital: ~45% bound to plasma proteins; acetaminophen: 10-25% bound; caffeine: 25-36% bound, primarily to albumin. |
| Volume of Distribution | Butalbital: 0.8 L/kg; acetaminophen: 0.9 L/kg; caffeine: 0.5 L/kg. Large Vd indicates extensive tissue distribution. |
| Bioavailability | Oral: 90-100% for butalbital and acetaminophen; caffeine ~100%. |
| Onset of Action | Oral: 30-60 minutes for analgesic effect. |
| Duration of Action | 4-6 hours for analgesic effect; butalbital's sedative effects may persist longer due to long half-life. |
| Molecular Weight | 263.28 |
1-2 capsules (50 mg butalbital, 325 mg acetaminophen, 40 mg caffeine) orally every 4 hours as needed, not to exceed 6 capsules per day.
| Dosage form | TABLET |
| Renal impairment | For CrCl <30 mL/min: avoid use or extend dosing interval to every 12 hours; not to exceed 4 doses per day. For dialysis: dose after hemodialysis. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce daily dose by 50% and monitor. Child-Pugh C: contraindicated. |
| Pediatric use | Children <12 years: not recommended. For ≥12 years, weight <50 kg: 1 capsule (50 mg butalbital, 325 mg acetaminophen, 40 mg caffeine) orally every 4 hours as needed, max 4 per day. |
| Geriatric use | Start with 1 capsule every 6 hours; monitor for sedation, confusion, and hepatotoxicity; reduce total daily dose if frail or low body weight. |
| 1st trimester | Avoid. Risk of neural tube defects and other congenital anomalies due to butalbital; also contains acetaminophen and caffeine, which have limited safety data. |
| 2nd trimester | Avoid. Butalbital may cause fetal dependence and withdrawal; acetaminophen is generally considered safe in therapeutic doses, but caution with caffeine. |
| 3rd trimester | Avoid. Butalbital can cause neonatal withdrawal syndrome and bleeding due to vitamin K deficiency; acetaminophen safe but caffeine may cause jitteriness. |
Clinical note
Comprehensive clinical and safety monograph for ESGIC (ESGIC).
| Placental transfer | Butalbital crosses the placenta readily; acetaminophen and caffeine also cross but to a lesser extent. |
| Breastfeeding | Butalbital is excreted into breast milk and may cause sedation and poor feeding in infants. Acetaminophen and caffeine are excreted in low amounts but caution is advised. Use only if clearly needed and monitor infant for drowsiness. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to barbiturates, acetaminophen, or caffeinePorphyriaSevere hepatic impairmentSevere renal impairmentConcurrent use of MAOIs (for butalbital component)Breastfeeding (relative, but caution advised)
| Precautions | Hepatotoxicity from acetaminophen (avoid exceeding 4 g/day; risk with alcohol use); butalbital dependence and withdrawal; CNS depression; impaired ability to drive or operate machinery; risk of medication-overuse headache; severe skin reactions (Stevens-Johnson syndrome) with acetaminophen; respiratory depression with high doses or in elderly/debilitated patients. |
| Food/Dietary | Caffeine content may interact with high-caffeine foods/beverages (coffee, tea, energy drinks), increasing risk of jitteriness, insomnia, or tachycardia. Grapefruit juice may increase caffeine levels. Alcohol potentiates acetaminophen hepatotoxicity and butalbital CNS depression; avoid concurrent use. |
Loading safety data…
| Lactation Rating | L3 - Moderately Safe |
| Teratogenic Risk | First trimester: Butalbital (barbiturate) is associated with increased risk of oral clefts and neural tube defects; acetaminophen and caffeine are generally considered low risk. Second and third trimesters: Butalbital may cause neonatal withdrawal syndrome and coagulopathy due to vitamin K deficiency; acetaminophen is safe at therapeutic doses; caffeine may be associated with reduced fetal growth at high intake. |
| Fetal Monitoring | Monitor maternal blood pressure, liver function, and signs of butalbital dependence. Fetal monitoring for growth restriction (caffeine effect) and neonatal withdrawal signs at delivery. |
| Fertility Effects | No significant known effects on fertility from acetaminophen or caffeine at therapeutic doses. Butalbital may cause hormonal imbalances affecting ovulation. |
| Clinical Pearls | ESGIC contains butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate with dependence potential; limit use to acute tension headaches (<10 days/month) to avoid medication-overuse headache. Acetaminophen hepatotoxicity risk increases with doses >4 g/day or concurrent alcohol use. Caffeine may cause withdrawal headaches if discontinued abruptly. |
| Patient Advice | Do not exceed recommended dose; daily acetaminophen limit is 4 g (4000 mg) from all sources. · Avoid alcohol while taking ESGIC to prevent liver damage. · Use only for tension headaches as directed; frequent use can lead to rebound headaches. · May cause drowsiness; avoid driving or operating machinery until effects are known. · Stop use and seek medical attention if you experience signs of liver injury (yellow skin/eyes, dark urine) or allergic reaction. · Do not combine with other products containing barbiturates, opioids, or sedatives without consulting your doctor. |